Drug Repurposing: Realities and Roadblocks

Drug Repurposing: Realities and Roadblocks We receive a steady stream of enquiries about opportunities in drug repurposing, often from people who see a short, low risk pathway to large upsides. But,...
Learn More

The race is on: after almost six decades, RSV vaccines near the finish line

The COVID-19 pandemic established that, when push comes to shove, successful vaccine development and deployment can be conducted at breakneck speed, even when largely untried and untested...
Learn More

For pharma & biotech, what's the value of a valuation?

When a client approaches us about conducting a valuation for them, our first question is always: why? If, for example, the reason is to help support them in a partnering negotiation, we proceed...
Learn More

Targeted protein degradation: a new pharmacology paradigm?

Traditional drug development focuses on targeting proteins with a defined binding pocket or active site to regulate protein activity. These strategies have exploited only around 400 of the 4000...
Learn More

What Happens to Pharma Valuations as Interest Rates Rise?

Everyone familiar with the risk-adjusted net present value method (rNPV) knows automatically that valuations decrease as the discount rate increases. This is indeed a fundamental tenet of the...
Learn More

Targeted Radiotherapy: The Comeback Kid of Cancer Treatment?

The notion that a systemically administered source of radiation can be usefully directed towards a tumor has been exploited since the 1940s, when radioiodine was introduced as a treatment for thyroid...
Learn More

Light Due Diligence: A Contradiction in Terms?

Alacrita has established itself as an industry specialist in due diligence (DD), conducting over 25 DD assignments per year, across therapeutic areas and technologies. Sometimes a prospective clients...
Learn More

Could COVID-19 be a catalyst for virtualizing clinical trials?

The virtualization of clinical trials has long been technically feasible, but cultural and regulatory barriers have prevented implementation. With over 1200 clinical trials worldwide being...
Learn More

Adapting to Our “New” Virtual Reality in Biotech

In the current crisis, working virtually is now a reality for many. The preparedness for this varies greatly. For some it’s business as usual, for others “going virtual” simply hasn’t been feasible,...
Learn More

Pipeline asset valuation: garbage in – garbage out

Methods of valuing pharmaceutical development-stage assets have been a perennial talking point for decades, and the advantages and disadvantages of each have been covered in numerous publications....
Learn More

COVID-19: a catalyst for anti-infective investing?

There has been a persistent call from early stage innovators to shine a spotlight on building anti-infective defenses in light of the looming crisis of antimicrobial resistance (AMR). Unfortunately,...
Learn More

The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More
1 2 3 4 5